DYRK1A and Dravet syndrome: DYRK1A inhibitors such as epigallocatechin-3-gallate (EGCG) have been proposed for therapy in DS, because several studies have demonstrated an amelioration of brain, cognitive, and craniofacial deficits associated with DS [5,17,19,20,21,22,23,24,25].